Sigrun Møgedal
MPP Chair from March 2016 to September 2017 Dr. Sigrun Møgedal guided the MPP during its period of expansion into tuberculosis and hepatitis C and oversaw the reform of the foundation’s governance and operational systems. She is a medical doctor and former Special Adviser to the Norwegian Institute of Public Health, former Ambassador for HIV/AIDS for Norway, and former Chair of the Board for the Global Health Workforce Alliance at the World Health Organization. Sigrun also served as a senior advisor to the Norwegian Agency for Development Cooperation (NORAD) and was awarded the status of Knight First Class in the Royal Norwegian Order of Saint Olav.
Charles Clift
MPP’s founding chairman and Chair from July 2010 to March 2016 Trained as an economist at Cambridge and Sussex Universities, Charles Clift has held a wide range of roles during his career as an economist with the United Kingdom’s (UK) Department for International Development (DFID). From 2001 to 2002, Charles was Head of the Secretariat of the UK Commission on Intellectual Property Rights. From 2004 to 2006, he was employed in a similar capacity by the World Health Organization Commission on Intellectual Property Rights, Innovation and Public Health, and was the principal consultant in drafting the report of the WHO’s Consultative Expert Working Group on Research and Development: Financing and Coordination. In recent years, Charles has worked extensively with other donors, the pharmaceutical industry, governments and civil society on ways to improve access to medicines in developing countries, including through the use of innovative intellectual property mechanisms.
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.